CAMBRIDGE, Mass., Aug. 2, 2016 /PRNewswire/ -- Evelo Biosciences today announced it has entered into an exclusive collaboration with Mayo Clinic investigators to advance immuno-microbiome-based therapies for cancer.
Under the terms of this agreement, Evelo will work with Mayo Clinic to isolate and characterize cancer-associated bacteria from patient stool samples and tumor biopsies. This work will contribute to Evelo's cancer-associated bacteria library, a key platform discovery tool for the development of onco-microbials to treat cancer. Evelo will advance specific cancer-associated bacteria as therapeutics based on their ability to activate the immune system against tumors.
"We are excited to work with Mayo Clinic, a world leader in cancer research," said Dr. Brian Goodman, Evelo's Head of Scientific Strategy. "Understanding how certain cancer-associated bacteria disrupt tumors is an important step toward developing new medicines for cancer."
"This collaboration supports Mayo Clinic's commitment to world leading science and the work of our investigators as we explore the cancer microbiome," says Andrea Mariani, M.D., professor of obstetrics and gynecology, Mayo Clinic. "We look forward to working with Evelo and on behalf of patients everywhere who may ultimately benefit from our activities."
Mayo Clinic has a financial interest in the company and technology referenced in this press release. Revenue Mayo Clinic receives from the activities described in this press release will be used to support its not-for-profit mission in patient care, education and research.
About Evelo Biosciences
Founded in 2014, Evelo Biosciences has established the leading therapeutics discovery and development platform based on the human immuno-microbiome, the inter-connected metasystem comprising the human immune system and the human microbiome. Evelo is developing onco-microbials for the treatment of cancer and immuno-microbials for the treatment of autoimmune and inflammatory diseases. The company is translating its insights into the immuno-microbiome into a range of product candidates, which are being advanced toward first human testing in 2017.
For more information, please visit www.evelobio.com.
SOURCE Evelo Biosciences